|Bid||46.92 x 800|
|Ask||52.00 x 800|
|Day's Range||47.37 - 50.01|
|52 Week Range||20.03 - 54.97|
|Beta (5Y Monthly)||1.27|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 24, 2021 - Mar 01, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||60.33|
REGENXBIO Inc. (Nasdaq: RGNX) today announced the closing of its previously announced underwritten public offering of 4,260,000 shares of its common stock at a price to the public of $47.00 per share, as well as the exercise in full of the underwriters' option to purchase 639,000 additional shares at the public offering price. Including the option exercise, the total gross proceeds to REGENXBIO are expected to be approximately $230.3 million, before deducting the underwriting discounts and commissions and estimated offering expenses.
REGENXBIO Inc. (Nasdaq: RGNX) today announced it will present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 at 11:40 a.m. ET. The conference will be held in a virtual meeting format.
The latest analyst coverage could presage a bad day for REGENXBIO Inc. ( NASDAQ:RGNX ), with the analysts making...